

Key information

Headquarters: Europe

AirInSpace B.V.
Delftech Park 26
2628 XH Delft, The Netherlands
Phone: +31 (15) 2600 930
Fax: +31 (15) 2600 931

AirInSpace S.A.S.

Zone d'activité du Pas du Lac
10 avenue Ampère - Bâtiment B2
78180 Montigny Le Bretonneux, France
Phone: +33 1 30 07 01 01
Fax: +33 1 30 07 01 02

Headquarters: United States

AirInSpace Inc.

46179 Westlake Drive, Suite 330
Sterling, VA 20165
Phone: +1 703 621 0671
Fax: +1 703 621 4535

Website: www.airinspace.com

Investors: Matignon Technologies,
Oddo AM, Baring Vostok
Capital Partners (BVCP)

Sector: Medical Devices
General Hospital

Employees: 30

Investor Contact: Laurent Fullana, CEO
AirInSpace
+31 (15) 2600 930

Media Contact: Ronald Trahan, APR
President
Ronald Trahan Asso. Inc.
+1 508 359 4005, x108

Leadership Team

Laurent Fullana

Chief Executive Officer

Wade Tetsuka

President, U.S. Operations

Vance Bergeron, PhD

Chief Scientific Officer

Anthony Lecomte

Chief Financial Officer

Patrick Aubert

Director, Air Transportation Market

Laurent Descotes, PhD

Director, Product Development &
Industrialization

Stephane Ortu

Dir., Business Unit Healthcare France

Advisory Board

Jean Michel Broun

Senior Partner and a Director of Baring
Vostok Capital Partners (Moscow)

Eliane Gluckman, MD, PhD

Medical Coord., Dept. of Hematology &
Oncology, Hospital Saint-Louis (Paris)

John H. Markels, PhD

Vice President of Operations in Europe,
Middle East and Africa for Merck & Co.

Eckhard Polzer

Former Chairman and Chief Executive
Officer of Dornier Medical International

AirInSpace owns a patented core technology, HEPA-MD™—the next generation of the Company's initial Plasmer™ platform—that inactivates lethal airborne microorganisms. Developed initially for use in Russia's MIR space station, the AirInSpace technology is in routine use today on the International Space Station (ISS). AirInSpace owns the exclusive rights to this one-of-a-kind technology, which shows up to 99.999% single-pass inactivation of airborne microorganisms. HEPA-MD technology is highly scalable and is being adapted by AirInSpace and its partners to a wide range of applications.

The Company's first potential 'homerun' product in the U.S., based on HEPA-MD technology, is its FDA cleared PlasmairT2006 by AirInSpace mobile device that captures and inactivates biological particles from the air for medical purposes. Conventional HEPA (High Efficiency Particulate Air) filters are the most common airborne-decontamination method used in hospitals, *but they do not inactivate the pathogens they trap* and can therefore serve as a reservoir for incubating more pathogens that can release into the air to pose a lethal risk to patients, staff and maintenance personnel. Indeed, hospital-acquired (*nosocomial*) infections affect nearly one in 10 patients in *developed countries*. New regulations are being imposed to control airborne contamination levels, requiring hospitals to undertake massive renovations to upgrade their ventilation systems. Alternatively, hospitals are finding unprecedented success with deployment of *PlasmairT2006* mobile units.

In addition to the hospital market (\$1.8 billion opportunity), AirInSpace has developed applications for other markets, such as air transportation. On longer flights when cabin air is re-circulated for hours, concentrations of biocontaminants may rise to dangerous levels, and passengers are exposed to a higher risk of cross-infection. The onboard SARS transmission in 2003 is an alarming example. AirInSpace's technology is now being installed in the main cabin ventilation systems of a major business jet manufacturer.

The Company believes its HEPA-MD technology is superior to all available and known air decontamination technologies. HEPA-MD technology offers critically unique advantages: (1) Microbe collection *and* inactivation; and (2) Physical efficiency (easy to get air through the system, no 'clogging', which means it is energy-friendly and less noisy). Nearly three dozen independent studies at prestigious academic labs such as Harvard School of Public Health (Boston) have tested HEPA-MD technology's efficacy.



AirInSpace's first potential 'homerun' product is PlasmairT2006, a mobile unit used by 100+ hospitals throughout France.

Germicidal Efficacy

Up to 99.999%

PlasmairT2006 inactivates harmful and resistant infectious microorganisms.

Cost Effective

New regs require action by hospital
Hospitals are under intense pressure to control airborne contamination. A mobile PlasmairT2006 unit offers an economical, reliable and immediate solution.

AJIC
American Journal of Infection Control
APPLIED EPIDEMIOLOGY IN HEALTH CARE SETTINGS AND THE COMMUNITY

Special Issue:
Airborne Transmission

Recommended practices for surveillance: Association for Professionals in Infection Control and Epidemiology (APIC), Inc.
TB Use, CDC, Phongsavan, P, Hsu, C, Orosco, J, Henschler

- Influenza vaccination of health care workers: Policies and practices of hospitals in a community setting
JH Galarraga, M Colman, PH Pitt, AR Herman, BS Roper, PL Washington, A Jansen, and WA Crumrine
- Working with symptoms of a respiratory infection: Staff who care for high-risk individuals
S Lurie, B Gostein, B Smith, and PH Weaver
- Evaluation of a new mobile system for protecting immunosuppressed patients against airborne contamination
JL Parot, JP Gangneux, A Fischer, M Mabernard, S Challer, N Laudret, and V Bergeron
- Isolation status and voice prompts improve hand hygiene
SP Swoboda, R Berling, K Wilkus, S Lurie, and PA Upson
- Tattooing in prisons—Not such a pretty picture
TE Nelson, DJ Abbot, and G Hooper
- On-site influenza vaccination arrangements improved influenza vaccination rate of employees of a tertiary hospital in Singapore
H Yang, Loo, and Y Tan Yong
- Pandemic influenza preparedness: A survey of businesses
PW Smith, K Hansen, S Gaudreau, and DJ Stud
- Absence of phylogenetic clustering of vaccinees following smallpox vaccination
SB Kilian, J Bates, PJ Wright, and RFS Edwards
- A modified "cover your cough" campaign prevents exposures of employees to portulaca at a children's hospital
A Chatterjee, S Phumman, R Jayaram, T Davidson, K Eichler, M Hall, and S Lazaroff

visit AJIC online at: www.ajicjournal.org

September 2007
Volume 35
Number 7

Official Publisher of
APIC
Association for Professionals in Infection Control and Epidemiology

M Mosby
ISBN 0789 6522